Hong Kong Doctors May Open Private Clinics In Guangdong
This article was originally published in PharmAsia News
According to the recent Supplement V to the Hong Kong-Mainland Closer Economic Partnership Arrangement, Guangdong will be the testing ground for a series of pilot plans by year end. In healthcare, Hong Kong permanent residents of Chinese nationality - who have been practicing in the territory of Macau for at least five years - may open clinics as sole investors upon receiving the mainland's certificate of licensed practicing physician. There is no investment limit for setting up a clinic, compared to the previous regulation restricting maximum Hong Kong funding to 70 percent of the total investment. Guangdong officials believe the pilot will provide valuable reference and experience for further boosting the development of the healthcare reform. (Click here for more - Chinese Language)
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.